Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2013 4
2014 1
2015 3
2016 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
BAP1 loss defines a new class of renal cell carcinoma.
Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, Leng N, Pavía-Jiménez A, Wang S, Yamasaki T, Zhrebker L, Sivanand S, Spence P, Kinch L, Hambuch T, Jain S, Lotan Y, Margulis V, Sagalowsky AI, Summerour PB, Kabbani W, Wong SW, Grishin N, Laurent M, Xie XJ, Haudenschild CD, Ross MT, Bentley DR, Kapur P, Brugarolas J. Peña-Llopis S, et al. Nat Genet. 2012 Jun 10;44(7):751-9. doi: 10.1038/ng.2323. Nat Genet. 2012. PMID: 22683710 Free PMC article.
Regulation of TFEB and V-ATPases by mTORC1.
Peña-Llopis S, Vega-Rubin-de-Celis S, Schwartz JC, Wolff NC, Tran TA, Zou L, Xie XJ, Corey DR, Brugarolas J. Peña-Llopis S, et al. EMBO J. 2011 Jul 29;30(16):3242-58. doi: 10.1038/emboj.2011.257. EMBO J. 2011. PMID: 21804531 Free PMC article.
A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma.
Sivanand S, Peña-Llopis S, Zhao H, Kucejova B, Spence P, Pavia-Jimenez A, Yamasaki T, McBride DJ, Gillen J, Wolff NC, Morlock L, Lotan Y, Raj GV, Sagalowsky A, Margulis V, Cadeddu JA, Ross MT, Bentley DR, Kabbani W, Xie XJ, Kapur P, Williams NS, Brugarolas J. Sivanand S, et al. Sci Transl Med. 2012 Jun 6;4(137):137ra75. doi: 10.1126/scitranslmed.3003643. Sci Transl Med. 2012. PMID: 22674553 Free PMC article.
Synthesis of a 2-aryl-3-aroyl indole salt (OXi8007) resembling combretastatin A-4 with application as a vascular disrupting agent.
Hadimani MB, Macdonough MT, Ghatak A, Strecker TE, Lopez R, Sriram M, Nguyen BL, Hall JJ, Kessler RJ, Shirali AR, Liu L, Garner CM, Pettit GR, Hamel E, Chaplin DJ, Mason RP, Trawick ML, Pinney KG. Hadimani MB, et al. J Nat Prod. 2013 Sep 27;76(9):1668-78. doi: 10.1021/np400374w. Epub 2013 Sep 9. J Nat Prod. 2013. PMID: 24016002 Free PMC article.
The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts.
Strecker TE, Odutola SO, Lopez R, Cooper MS, Tidmore JK, Charlton-Sevcik AK, Li L, MacDonough MT, Hadimani MB, Ghatak A, Liu L, Chaplin DJ, Mason RP, Pinney KG, Trawick ML. Strecker TE, et al. Cancer Lett. 2015 Dec 1;369(1):229-41. doi: 10.1016/j.canlet.2015.08.021. Epub 2015 Sep 1. Cancer Lett. 2015. PMID: 26325604 Free PMC article.
Radiation-enhanced lung cancer progression in a transgenic mouse model of lung cancer is predictive of outcomes in human lung and breast cancer.
Delgado O, Batten KG, Richardson JA, Xie XJ, Gazdar AF, Kaisani AA, Girard L, Behrens C, Suraokar M, Fasciani G, Wright WE, Story MD, Wistuba II, Minna JD, Shay JW. Delgado O, et al. Clin Cancer Res. 2014 Mar 15;20(6):1610-22. doi: 10.1158/1078-0432.CCR-13-2589. Epub 2014 Jan 31. Clin Cancer Res. 2014. PMID: 24486591 Free PMC article.
11 results